Very long-term outcomes after a single catheter ablation procedure for the treatment of atrial fibrillation—the protective role of antiarrhythmic drug therapy

2018 ◽  
Vol 52 (1) ◽  
pp. 39-45 ◽  
Author(s):  
João Mesquita ◽  
Diogo Cavaco ◽  
António Miguel Ferreira ◽  
Francisco Moscoso Costa ◽  
Pedro Carmo ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Drug Therapy ◽  
Catheter Ablation ◽  
Antiarrhythmic Drug ◽  
Protective Role ◽  
Long Term Outcomes ◽  
Ablation Procedure ◽  
Antiarrhythmic Drug Therapy

scholarly journals Progression of atrial fibrillation after catheter ablation procedure and antiarrhythmic drug therapy in patients with paroxysmal AF

2016 ◽  
Vol 20 (3) ◽  
pp. 72
Author(s):  
A A Simonyan ◽  
V N Kolesnikov ◽  
L I Vilenskiy ◽  
Yu S Krivosheev ◽  
D I Bashta ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Drug Therapy ◽  
Catheter Ablation ◽  
Antiarrhythmic Drug ◽  
Conflict Of Interest ◽  
Complication Rate ◽  
Ablation Procedure ◽  
Antiarrhythmic Drug Therapy ◽  
Group I

<p><strong>Aim.</strong> This prospective randomized study was aimed to assess the progression of atrial fibrillation (AF) after ablation procedure and antiarrhythmic drug therapy (AAD) in patients with paroxysmal AF by means of implantable cardiac monitors (ICM). <br /><strong>Methods.</strong> The study enrolled 92 patients with paroxysmal AF, who were eligible either for catheter ablation or AAD. The patients were randomized into two groups: 1) AAD + ICM implantation (group I; n=46), and 2) AF catheter ablation (CA) + ICM implantation (group II; n=46), and 2). The primary endpoint was AF progression according to ICM data. The AF progression was defined as AF burden &gt; 30%. A complication rate after ablation procedure and side effects of AAD were determined as the secondary endpoints. The follow up of this study was 24 months. <br /><strong>Results</strong>. By the end of the follow-up period, AF progression was observed in 27 (58.7%) patients in the AAD group and 10 (21.7%) patients in the CA group (р=0.0003; HR 0.37, 95% CI [0.17-0.76], р=0.007, Cox regression). 13 (28,3%) patients in the AAD group and 2 (4.3%) in the CA group (р=0.002) developed persistent AF. The complication rate in the AAD group was 24% (11 patients) and 6.5 % (3 patients) in the CA group (р=0.02).<br /><strong>Conclusion.</strong> Radiofrequency ablation of AF leads to a significant decrease in AF progression when compared with antiarrhythmic drug therapy in patients with paroxysmal AF, which was confirmed by implantable cardiac monitors data.</p><p>Received 12 July 2016. Accepted 22 August 2016.</p><p><strong>Funding:</strong> The study had no sponsorship.<br /><strong>Conflict of interest:</strong> The authors declare no conflict of interest.</p>

scholarly journals Antiarrhythmic drug therapy after catheter ablation for atrial fibrillation has no impact on recurrences, cardiovascular events and mortality – insights from the German Ablation Registry

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
R Schleberger ◽  
A Metzner ◽  
K H Kuck ◽  
D Andresen ◽  
S Willems ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Drug Therapy ◽  
Catheter Ablation ◽  
Antiarrhythmic Drug ◽  
Treatment Satisfaction ◽  
Cardiovascular Events ◽  
Patient Reported Outcome ◽  
Antiarrhythmic Drug Therapy ◽  
Funding Sources ◽  
Patient Reported

Abstract Background Data on the optimal treatment strategy for antiarrhythmic drug therapy (AAD) after atrial fibrillation (AF) catheter ablation are inconsistent. While AAD potentially stabilizes sinus rhythm, it also increases the patients' treatment burden. Methods Patients from the prospective German Ablation Registry (n=3275) discharged with or without AAD after AF catheter ablation were compared regarding long-term success, cardiovascular events and patient reported outcome. Results In patients with paroxysmal AF (n=2138) recurrence and rehospitalization rates did not differ when discharged with (n=1051) or without (n=1087) AAD (recurrence: adjusted odds ratio (OR) 1.13, 95% confidence interval (CI) [0.95–1.35]; rehospitalization: OR 1.08, 95% CI [0.90–1.30]). The reablation rate was higher and reduced treatment satisfaction was reported more often in those discharged with AAD (reablation: OR 1.30, 95% CI [1.05–1.61]; reduced treatment satisfaction: OR 1.76, 95% CI [1.20–2.58]). Similar rates of recurrences, rehospitalisations, reablations and treatment satisfaction were found in patients with persistent AF (n=1137) discharged with (n=641) or without (n=496) AAD (recurrence: OR 1.22, 95% CI [0.95–1.56]; rehospitalization: OR 1.16, 95% CI [0.90–1.50]; reablation: OR 1.21, 95% CI [0.91–1.61]; treatment satisfaction: OR 1.24, 95% CI [0.74–2.08]). The incidence of cardiovascular events and mortality did not differ at follow-up in paroxysmal and persistent AF patients discharged with or without AAD. Conclusion The rates of recurrences, cardiovascular events and mortality did not differ between patients discharged with or without AAD after AF catheter ablation. However, AAD should be considered carefully in patients with paroxysmal AF, in whom it was associated with a higher reablation rate and reduced treatment satisfaction. FUNDunding Acknowledgement Type of funding sources: None.

scholarly journals Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design

2018 ◽  
Vol 199 ◽  
pp. 192-199 ◽  
Author(s):  
Douglas L. Packer ◽  
Daniel B. Mark ◽  
Richard A Robb ◽  
Kristi H. Monahan ◽  
Tristram D. Bahnson ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Drug Therapy ◽  
Catheter Ablation ◽  
Antiarrhythmic Drug ◽  
Antiarrhythmic Drug Therapy

scholarly journals Impact of postprocedural antiarrhythmic drug therapy with bepridil on maintaining sinus rhythm after catheter ablation for persistent atrial fibrillation

2016 ◽  
Vol 68 (3) ◽  
pp. 229-235 ◽  
Author(s):  
Takehito Kondo ◽  
Junichiro Miake ◽  
Masaru Kato ◽  
Kazuyoshi Ogura ◽  
Kazuhiko Iitsuka ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Drug Therapy ◽  
Catheter Ablation ◽  
Sinus Rhythm ◽  
Antiarrhythmic Drug ◽  
Persistent Atrial Fibrillation ◽  
Antiarrhythmic Drug Therapy

scholarly journals Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial

2020 ◽  
Vol 75 (25) ◽  
pp. 3105-3118 ◽  
Author(s):  
Jeanne E. Poole ◽  
Tristram D. Bahnson ◽  
Kristi H. Monahan ◽  
George Johnson ◽  
Hoss Rostami ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Drug Therapy ◽  
Catheter Ablation ◽  
Antiarrhythmic Drug ◽  
Antiarrhythmic Drug Therapy
Sign in / Sign up

Export Citation Format

Share Document